KYMERA THERAPEUTICS, INC. Research and Development Expense
KYMERA THERAPEUTICS, INC. (KYMR) reported Research and Development Expense of $119.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $119.48M, a 52.42% increase year-over-year.
- KYMERA THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $98.16M, a 22.31% increase year-over-year.
- KYMERA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $83.83M, a 16.73% increase year-over-year.
- KYMERA THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $74.09M, a 22.65% increase year-over-year.
- KYMERA THERAPEUTICS, INC. research and development expense for fiscal 2025 was $316.57M, a 31.77% increase from fiscal 2024.
- KYMERA THERAPEUTICS, INC. research and development expense for fiscal 2024 was $240.25M, a 27.06% increase from fiscal 2023.
- KYMERA THERAPEUTICS, INC. research and development expense for fiscal 2023 was $189.08M, a 15.12% increase from fiscal 2022.
- KYMERA THERAPEUTICS, INC. research and development expense for fiscal 2022 was $164.25M, a 19.87% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $119.48M 10-Q · filed 2026-08-05 | $217.64M 10-Q · filed 2026-08-05 | $301.47M derived: sum of 3 quarters · filed 2026-08-05 | $375.57M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $98.16M 10-Q · filed 2026-04-30 | $181.99M derived: sum of 2 quarters · filed 2026-04-30 | $256.09M derived: sum of 3 quarters · filed 2026-04-30 | $334.48M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $83.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $157.93M derived: sum of 2 quarters · filed 2026-02-26 | $236.31M derived: sum of 3 quarters · filed 2026-08-05 | $316.57M 10-K · filed 2026-02-26 |
| 2025-09-30 | $74.09M 10-Q · filed 2025-11-04 | $152.48M derived: sum of 2 quarters · filed 2026-08-05 | $232.74M 10-Q · filed 2025-11-04 | $304.55M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $78.39M 10-Q · filed 2026-08-05 | $158.64M 10-Q · filed 2026-08-05 | $230.46M derived: sum of 3 quarters · filed 2026-08-05 | $290.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $80.25M 10-Q · filed 2026-04-30 | $152.07M derived: sum of 2 quarters · filed 2026-04-30 | $212.48M derived: sum of 3 quarters · filed 2026-04-30 | $271.68M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $71.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $132.23M derived: sum of 2 quarters · filed 2026-02-26 | $191.43M derived: sum of 3 quarters · filed 2026-02-26 | $240.25M 10-K · filed 2026-02-26 |
| 2024-09-30 | $60.41M 10-Q · filed 2025-11-04 | $119.61M derived: sum of 2 quarters · filed 2025-11-04 | $168.43M 10-Q · filed 2025-11-04 | $221.40M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $59.20M 10-Q · filed 2025-08-11 | $108.02M 10-Q · filed 2025-08-11 | $160.99M derived: sum of 3 quarters · filed 2026-02-26 | $209.11M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $48.82M 10-Q · filed 2025-05-09 | $101.79M derived: sum of 2 quarters · filed 2026-02-26 | $149.91M derived: sum of 3 quarters · filed 2026-02-26 | $195.67M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $52.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $101.09M derived: sum of 2 quarters · filed 2026-02-26 | $146.85M derived: sum of 3 quarters · filed 2026-02-26 | $189.08M 10-K · filed 2026-02-26 |
| 2023-09-30 | $48.12M 10-Q · filed 2024-10-31 | $93.88M derived: sum of 2 quarters · filed 2024-10-31 | $136.11M 10-Q · filed 2024-10-31 | $179.24M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $45.77M 10-Q · filed 2024-08-07 | $87.99M 10-Q · filed 2024-08-07 | $131.13M derived: sum of 3 quarters · filed 2025-02-27 | $175.00M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $42.23M 10-Q · filed 2024-05-02 | $85.36M derived: sum of 2 quarters · filed 2025-02-27 | $129.24M derived: sum of 3 quarters · filed 2025-02-27 | $170.53M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $43.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $87.01M derived: sum of 2 quarters · filed 2025-02-27 | $128.30M derived: sum of 3 quarters · filed 2025-02-27 | $164.25M 10-K · filed 2025-02-27 |
| 2022-09-30 | $43.88M 10-Q · filed 2023-11-02 | $85.17M derived: sum of 2 quarters · filed 2023-11-02 | $121.11M 10-Q · filed 2023-11-02 | $158.64M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $41.29M 10-Q · filed 2023-08-03 | $77.24M 10-Q · filed 2023-08-03 | $114.77M derived: sum of 3 quarters · filed 2024-02-22 | $153.07M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $35.94M 10-Q · filed 2023-05-04 | $73.47M derived: sum of 2 quarters · filed 2024-02-22 | $111.78M derived: sum of 3 quarters · filed 2024-02-22 | $147.00M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $37.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $75.83M derived: sum of 2 quarters · filed 2024-02-22 | $111.06M derived: sum of 3 quarters · filed 2024-02-22 | $137.02M 10-K · filed 2024-02-22 |
| 2021-09-30 | $38.31M 10-Q · filed 2022-11-03 | $73.53M derived: sum of 2 quarters · filed 2022-11-03 | $99.49M 10-Q · filed 2022-11-03 | $119.88M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $35.22M 10-Q · filed 2022-08-09 | $61.18M 10-Q · filed 2022-08-09 | $81.57M derived: sum of 3 quarters · filed 2023-02-23 | $97.35M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $25.96M 10-Q · filed 2022-05-03 | $46.35M derived: sum of 2 quarters · filed 2023-02-23 | $62.13M derived: sum of 3 quarters · filed 2023-02-23 | $75.95M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $20.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $36.17M derived: sum of 2 quarters · filed 2023-02-23 | $49.99M derived: sum of 3 quarters · filed 2023-02-23 | $62.10M 10-K · filed 2023-02-23 |
| 2020-09-30 | $15.78M 10-Q · filed 2021-11-10 | $29.60M derived: sum of 2 quarters · filed 2021-11-10 | $41.71M 10-Q · filed 2021-11-10 | $52.80M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $13.82M 10-Q · filed 2021-08-06 | $25.93M 10-Q · filed 2021-08-06 | $37.02M derived: sum of 3 quarters · filed 2022-02-24 | $48.33M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $12.12M 10-Q · filed 2021-05-06 | $23.20M derived: sum of 2 quarters · filed 2022-02-24 | $34.51M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | $11.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $22.40M derived: sum of 2 quarters · filed 2022-02-24 | $37.16M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $11.31M 10-Q · filed 2020-11-05 | $26.07M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |